Heron Therapeutics, Inc.

Equities

HRTX

US4277461020

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:02 17/05/2024 am IST			After market 02:13:46 am
3.21 ^USD	+7.00%		3.215	+0.16%

15/05	Transcript : Heron Therapeutics, Inc. - Analyst/Investor Day
07/05	Transcript : Heron Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024

Heron Therapeutics, Inc. Provides Financial Guidance for the Year 2023 and 2024

November 15, 2023 at 02:35 am IST

Heron Therapeutics, Inc. provided financial guidance for the year 2023 and 2024. Full-year 2023 net product sales are expected to be in the range of $123 million to $125 million.

Full-year 2024 net product sales are expected to be in the range of $138 million to $158 million.

Latest news about Heron Therapeutics, Inc.

Transcript : Heron Therapeutics, Inc. - Analyst/Investor Day	15/05
Transcript : Heron Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024	07/05
Heron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Capital One Starts Heron Therapeutics With Overweight Rating, $6 Price Target	23/04	MT
Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024	22/03	CI
Health Care Down on Rotation to Rate-Sensitive Sectors -- Health Care Roundup	14/03	DJ
Sector Update: Health Care Stocks Slipping Late Afternoon	14/03	MT
Heron Therapeutics Shares Soar After Q4 Results Beat	13/03	MT
Needham Adjusts Price Target on Heron Therapeutics to $5 From $4, Keeps Buy Rating	13/03	MT
Transcript : Heron Therapeutics, Inc., Q4 2023 Earnings Call, Mar 12, 2024	13/03
Heron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03	CI
Earnings Flash (HRTX) HERON THERAPEUTICS Posts Q4 Revenue $34.2M, vs. Street Est of $31.2M	13/03	MT
Heron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	13/03	CI
Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024	13/03	CI
Heron Therapeutics Shares Rise 15% After FDA Approves Expanded Use of Zynrelef	24/01	DJ
Heron Therapeutics Says FDA Approved Expanded Label for Zynrelef to Add More Orthopedic, Soft Tissue Procedures	24/01	MT
Heron Therapeutics, Inc. Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures	24/01	CI
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Monday Amid Boeing 737 Max 9 Grounding	08/01	MT
Heron Therapeutics Unveils Deal to Expand Sales Network for Postoperative Pain Control Anesthetic; Shares Rise Premarket	08/01	MT
Heron Therapeutics, Inc. Enters into Five-Year Distributor Partnership with Crosslink Life Sciences, LLC to Expand the Sales Network Supporting ZYNRELEF	08/01	CI
Kevin Kotler Resigns as A Member of the Board of Directors of Heron Therapeutics, Inc., Effective December 31, 2023	22/12	CI
Heron Therapeutics Insider Bought Shares Worth $137,970, According to a Recent SEC Filing	17/11	MT
Needham Trims Price Target on Heron Therapeutics to $4 From $5, Keeps Buy Rating	15/11	MT
Transcript : Heron Therapeutics, Inc., Q3 2023 Earnings Call, Nov 14, 2023	15/11
Earnings Flash (HRTX) HERON THERAPEUTICS Posts Q3 Revenue $31.4M, vs. Street Est of $31.8M	15/11	MT

Chart Heron Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.

Sector

Biotechnology & Medical Research

Calendar

13/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Heron Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3 USD

Average target price

6.75 USD

Spread / Average Target

+125.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HERON THERAPEUTICS, INC.	+88.82%	45Cr
MODERNA, INC.	+33.37%	4.95TCr
IQVIA HOLDINGS INC.	+1.55%	4.26TCr
LONZA GROUP AG	+49.11%	4.25TCr
CELLTRION, INC.	-4.22%	2.91TCr
ICON PUBLIC LIMITED COMPANY	+11.57%	2.66TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	1.86TCr
BIO-TECHNE CORPORATION	+7.36%	1.32TCr
MEDPACE HOLDINGS, INC.	+28.30%	1.25TCr
UNITED THERAPEUTICS CORPORATION	+23.80%	1.21TCr

Other Biotechnology & Medical Research